-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On April 26, Sanofi announced the positive results of phase III (MELODY) clinical results of nirsevimab used to prevent lower respiratory tract infections caused by respiratory syncytial virus (RSV).
Primary endpoint: Compared with placebo, nirsevimab significantly reduced lower respiratory tract infections caused by RSV in healthy premature and full-term infants after a RSV epidemic season.
In terms of safety: there was no significant difference between the nirsevimab group and the placebo group.
The overall safety of the nirsevimab group is consistent with previously reported results.
This result will become the basic data for the listing application of nirsevimab.
Palivizumab is the first monoclonal antibody used to prevent lower respiratory tract infections caused by respiratory syncytial virus (RSV).
RSV is an infectious virus that causes respiratory tract infections.
Nirsevimab was jointly developed by Sanofi and AstraZeneca.
In July 2020, the "New England Journal of Medicine" announced the results of the phase II clinical trial of nirsevimab.
